Science Behind One of Brainz Power's 9 ingredients- Bacopa Monniera

Study of Bocopa Monnieri from Journal of Alternative and Complementary Medicine & The National Insitute of Health "Effercts of a Standardized Bocopa Monnieri Extract on Cognitive Performance, Anxiety, and Depression in the Elderly: A Rondomized, Double- Blind, Placebo- Controlled Trial"

Bacopa monnieri (L.) Pennel has been used for centuries in Ayurvedic medicine, either alone or in combination with other herbs, as a memory and learning enhancer, sedative, and anti-epileptic. It grows in wet tropical environments, and, under its common English name of water hyssop, is a popular aquarium plant. It has drawn the interest of phytotherapists and pharmacologists, and an Australian survey showed it to be one of the most popular aid for memory.

Animal studies of B. monnieri whole plant or alcohol extracts have reported cognition-enhancing effects including improved motor learning and acquisition, consolidation, and retention of memory in rats.Memory-enhancing effects have been attributed to saponins (bacosides, bacopasides, or bacopasaponins). Bacopasaponin constituents have been shown to facilitate mental retention in avoidance response in rats,and to reverse amnesic effects of neurotoxin, scopolamine, phenytoin, electroshock, and immobilization stress. Hypothesized mechanisms of action include cholinergic upregulation, γ-aminobutyric acid–ergic modulation, antioxidant effects,, protein synthesis in the brain, 5-HT agonism, and modulation of brain stress hormones. Bacopa extracts have also ameliorated neurotoxic effects of nicotine and aluminum and reduced β-amyloid levels in the brain of a doubly transgenic mouse model of rapid amyloid deposition (PSAPP mice), suggesting mechanisms of action relevant to Alzheimer's disease

Bacopa alcohol extract has shown memory-enhancing effects in three double-blind, randomized, placebo-controlled studies. A trial in 46 healthy volunteers 18–60 years old by Stough et al. evaluated their performance on a battery of cognitive tests after 5 weeks and after 12 weeks of 300 mg of B. monnieri extract daily. The investigators reported significant improvements in measures of the Rey Auditory Verbal Learning Test (AVLT) and in State Anxiety. Another 3-month study in 76 healthy adults, 40–65 years old, showed an effect of Bacopa on the retention of new information in delayed recall of word pairs. A third trial in those over 55 with age-associated memory impairment, again with 3 months of treatment, showed more improvements at 12 weeks on subsets of the Wechsler Memory Scale with no loss of the cognitive gains 4 weeks after ending active treatment. Conversely, in a single dose study of Bacopa extract in which neuropsychological testing was performed 2 hours after administration, no differences were found between groups. A study by the same investigators with 4 weeks' treatment by a combination of Gingko biloba(maidenhair tree) 120 mg and Bacopa 300 mg in 85 healthy participants also did not show cognitive enhancement. Stough's study showed effects at 12 weeks but not at 5 weeks, suggesting that cognitive effects with Bacopa may take months to appear. Two uncontrolled trials have reported memory- and learning-enhancing effects of Bacopa with long-term dosing in children and in patients with anxiety neurosis.

Using a rigorous design, the results demonstrate that Bacopa has positive benefits on multiple measures of cognitive performance and affect. Bacopa recipients improved in delayed recall memory and Stroop task reaction times over the course of the study while placebo recipients remained stable on both. Bacoparecipients displayed a decrease in depression and combined state plus trait anxiety scores with the placebo recipients increasing on both. Participants also had slightly lower heart rates after taking Bacopa while those taking the placebo displayed an increase in heart rate. No effects were shown on the immediate recall task, divided attention task, the WAIS digit span task, mood states, blood pressure, and body temperature.

This study provides further evidence that standardized extracts of B. monnieri have potential for safely enhancing cognitive performance in aging, an indication that is closely comparable to the traditional uses of the herb. Whether this effect is due to a direct mechanism in which the active agents in B. monnieri act upon brain chemistry to influence memory processes or to greater tolerance for frustration, or due to decreasing the performance-degrading effects of arousal on complex tasks, or yet some other mechanism, remains to be explored.

Read More about this study from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153866/

Read more →

University of Maryland Medical Center Researched the ingredient Huperzine-A One of Brainz Power's Ingredients

University of Maryland Medical Center Researched the ingredient Huperzine-A

Follow these tips for a healthy diet:

  • Eat antioxidant foods, including fruits (such as blueberries, cherries, and tomatoes) and vegetables (such as squash and bell peppers).
  • Eat foods high in B-vitamins and calcium, such as almonds, beans, whole grains, dark leafy greens (such as spinach and kale), and sea vegetables such as kelp and dulse.
  • Eat more high-fiber foods, including beans, oats, and root vegetables (such as potatoes and yams).
  • Avoid refined foods such as white breads, pastas, and especially sugar.
  • Eat fewer red meats and more lean meats and cold-water fish.
  • Use healthy oils in foods, such as olive oil
  • Reduce or eliminate trans-fats, found in commercially-baked goods, such as cookies, crackers, cakes, French fries, onion rings, donuts, processed foods, and margarine.
  • DO NOT smoke.
  • Drink 6 to 8 glasses of filtered water daily.
  • Exercise at least 30 minutes daily, 5 days a week.

 

  • Ginkgo (Ginkgo biloba) shows some evidence for treating early Alzheimer disease and vascular dementia. However, one large randomized, double-blind, placebo-controlled study found that ginkgo did not prevent Alzheimer disease or dementia. If you are taking blood-thinning medication, such as warfarin (Coumadin), clopidogrel (Plavix), or aspirin, DO NOT use ginkgo without your doctor's supervision.
  • Huperzine A, a chemical made from the plant Huperzia serrata, may improve memory in both vascular and Alzheimer dementia, according to several studies in China. More research is needed. Huperzine A may slow your heart rate and can interact with many medications. DO NOT take huperzine A if you have liver disease, or if you are about to have anesthesia. Huperzine A may be associated with gastrointestinal blockage. There is also concern that Huperzine A may worsen emphysema. Talk to your doctor before taking huperzine A if you already take medicine to treat Alzheimer disease.
  • Bacopa (Bacopa monnieri) leaf extract, called Brahmi, is used in Ayurvedic or Indian medicine to improve brain function and learning. However, no scientific studies have looked at bacopa to see whether it might work for dementia. One study found that 300 mg per day for 12 weeks seemed to improve brain function in healthy people. Bacopa may slow your heart rate. People with stomach ulcers, intestinal problems, or emphysema should not tale bacopa.
  • Vinpocetine (isolated from Vinca minor) may increase blood flow to the brain and help the brain use oxygen better. More research is needed. Vinpocetine may interact with blood-thinning medicines such as warfarin (Coumadin), clopidogrel (Plavix), and aspirin.

Read more at the below

http://umm.edu/health/medical/altmed/condition/alzheimers-disease

Read more →

Huperzine-A: The Proven Therapeutic Treatment for Memory Loss- Article Talking More In Depth About One Of Brainz Power's Ingredients

Health care professionals are sounding the alarm that Alzheimer's disease will be an epidemic of astronomical proportions for the Baby Boom generation. According to a recent report released by Boston University's School of Medicine, women over 55 face a one in four lifetime risk of developing Alzheimer's disease, and men a one in six chance.2 But here's some good news.

Huperzine-A, an alkaloid extracted from a Chinese moss, Huperzia serrata, is showing great promise as a therapeutic treatment for Alzheimer's disease and other memory loss disorders. It has a long history of use in traditional Chinese medicine.3 It has been approved as a drug in China to treat Alzheimer's disease and other age-associated memory impairments, and is marketed in the U.S. as a dietary supplement.4 It also helps improve memory and learning in adolescent students.

How does it work?

First, it's important to understand how acetylcholine works. This messenger molecule is the most abundant and essential neurotransmitter in the brain that is responsible for numerous functions, including many related to cognition and memory. Acetylcholine is released into the synapse, or space between two nerve cells, where it stimulates the transfer of nerve impulses from one nerve cell to another. After the nerve impulse is transmitted, acetylcholinesterase—an enzyme that is found between nerve endings—breaks down acetylcholine into choline and acetate, and the nerve signal ends.

Loss of acetylcholine function is a primary feature of several types of brain dysfunction, including Alzheimer's disease. In Alzheimer's disease and senile dementia, acetylcholine is destroyed too quickly, and consequently the nerve impulse is either too weak to be received or it is incompletely transmitted between nerve cells. A shortage of acetylcholine is considered the most common cause of memory loss, decreased learning ability and intelligence. Additionally, the greatest amount of damage in the Alzheimer's brain is in the cells using acetylcholine.5 Huperzine-A inhibits the activity of acetylcholinesterase, so the breakdown of acetylcholine is slowed and the strength and duration of the nerve impulse is improved. Fortunately, based on scientific studies in both human and animal models, we now know that Huperzine-A makes more acetylcholine available for better brain functioning, and that it is a promising supplement for reversing and/or slowing down Alzheimer's disease and other brain disorders. Animal studies have also shown that Huperzine can protect against environmental poisoning and that it reduces glutamate-induced cell death.6

Scientific studies

In a 1995 double-blind, placebo controlled study at Zhejiang Medical University, in Hangzhou, China, 50 Alzheimer's patients received 200 mcg of Huperzine-A and 53 received a placebo for 8 weeks. All the patients were evaluated with several memory exams, including the Wechsler memory scale and the mini-mental state examination scale. At the end of the study, about 58% (29/50) of the patients treated with Huperzine-A showed significant improvements in their memory, cognitive, and behavioral functions versus only 36% of those receiving the placebo. There were no adverse side effects reported, and the researchers said, "Huperzine is a promising drug for symptomatic treatment of Alzheimer's disease." 7 

In a more recent study, Huperzine-A was tested on 202 mild to moderate Alzheimer's patients at the Peking Medical College Hospital in Beijing, China. One group was given 400 mcg of Huperzine-A per day for 12 weeks, and the other group was given a placebo. All patients were assessed with tests that evaluated their cognitive function, daily life activity and non-cognitive disorders, such as muscle control. The group treated with Huperzine-A showed remarkable improvement in cognition, behavior and mood, in comparison to the placebo group. There were no side effects except for a few reports of very mild insomnia and water retention in a few patients, and these effects were transient.8

Huperzine-A protects against free radicals

In addition to its acetylcholine enhancing effects, Huperzine-A was found to protect against free radical-induced cell toxicity in lab tests.9 This is significant because many modern diseases are believed to be the result of free radical damage. Huperzine has also been shown to dramatically decrease the abnormally elevated free radical activity in both the brain of old animals10, and the blood of Alzheimer's victims11 . This protective effect has been noted by scientists to be a significant additional benefit of Huperzine-A, beyond its acetylcholine enhancing effect.

Reverses effects of amnesia

Scopolamine is a class of drugs that can induce amnesia, which works by interfering with acetylcholine. A study performed on young and old monkeys given the drug showed that Huperzine-A reversed the deficits in performance and memory that result from scopolamine, suggesting that Huperzine-A may benefit cognitive impairments in patients with Alzheimer's disease and other memory disorders.12

Read more a the following link 

http://www.smart-publications.com/articles/huperzine-a-the-proven-therapeutic-treatment-for-memory-loss

Read more →

Huperzine-A Shows Promise in the Battle Against Alzheimer's Disease- Inside Look Into The Research Done On One Of Brainz Power's Ingredients

Currently there are an estimated 30 million people worldwide with Alzheimer’s disease (AD). Two thirds of them live in developing countries. This figure is set to increase to more than 100 million people by 2050. Much of this increase will be in rapidly developing and heavily populated regions such as China and Latin America.

With no known cure, AD is one of the most expensive diseases in the world to treat. The good news is that Huperzine-A is a natural cholinesterase inhibitor that offers neuroprotective properties, without side effects. Recent studies show that Huperzine-A is a strong candidate for stopping the progression of the disease.

Recent scientific studies

The first double-blind phase 2 clinical trial of Huperzine-A in mild to-moderate Alzheimer’s patients recently concluded in the U.S. The multi-center study evaluated 210 patients and was done in collaboration with the National Institute on Aging and the Alzheimer's Disease Cooperative Study Group (ADCS). The trial compared the safety, tolerability and efficacy of either 200 or 400 mcg of Huperzine-A administered orally twice a day for 16 weeks versus placebo. The study measured the efficacy of Huperzine-A on cognitive function, daily living activities and behavior.

The data demonstrated that the patients taking the higher dose of 400 mcg of Huperzine-A showed cognitive improvement at week 11 of treatment and at 16 weeks compared to placebo.

Paul Aisen, MD, Director of the ADCS, Professor of Neurosciences at the University of California, San Diego, and Principal Investigator for this clinical study stated, "This US Phase II trial has clearly demonstrated efficacy of Huperzine-A in the treatment of AD.” 1

A recent study at the Shanghai Jiaotong University School of Medicine, Shanghai, China, provided an updated meta-analysis of the efficacy and safety of Huperzine-A in AD. The scientists searched for randomized trials comparing Huperzine-A with placebo in the treatment of AD.

They found that taking 300 to 500 mcg a day of Huperzine-A for 8 to 24 weeks led to significant improvement in the patients’ performance on the mini-mental state examination (MMSE) and activities of daily living scale (ADL). (The MMSE and ADL are both diagnostic tools used to assess cognition.) The researchers concluded that Huperzine-A is a well-tolerated herbal medicine that could significantly improve cognitive performance in patients with AD.2

Looking forward

Huperzine-A has attracted widespread attention because of its unique pharmacological activities and low toxicity. As a result, Huperzine-A is becoming an important compound to treat AD.

However, Huperzine-A is obtained naturally from very limited and slowly growing natural resources and the content of Huperzine-A is very low in the raw plant material. This has led to strong interest in developing other sources of Huperzine-A. The Department of Plant Sciences and the BIO5 Institute at the University of Arizona has developed a method to propagate a member of the same plant species that produces high levels of Huperzine-A. The in vitro propagated tissues produce even higher levels of Huperzine-A than the natural plant, and the scientists are hopeful that they have discovered another excellent source for Huperzine-A.3

Hopefully, with research studies like these, we will soon see a remedy for one of the most dreaded diseases of the 21st century.

Read More at the link below 

http://www.smart-publications.com/articles/huperzine-a-shows-promise-in-the-battle-against-alzheimers-disease

Read more →

Science Behind 1 of Brainz Power's 9 Ingredints- Huperzine-A

The following report about Huperzine-A is from the American Academy of Neurology, The most widely read and highly cited peer-reviewed neurology journal. 

Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serratathat may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD).

Huperzine A is an alkaloid extract of the plant Huperzia serrata that may be useful as a treatment for Alzheimer disease (AD). During the 1980s, investigators in China determined that huperzine A is a potent inhibitor of acetylcholinesterase (AChE), a finding that has been confirmed repeatedly., It is highly selective for AChE in vitro, it has good brain penetration, and it is relatively free of cholinergic toxicity. In addition, some studies have shown that huperzine A may shift amyloid precursor protein (APP) metabolism toward the nonamyloidogenic α-secretase pathway. Based on the 50% inhibitory concentration (IC50), huperzine A is more potent than tacrine, physostigmine, and galantamine with respect to inhibition of AChE activity. Hence, it is presumed that huperzine A, if efficacious, would exert its clinical efficacy in AD via this mechanism. Certainly, it should be noted that huperzine has been shown to exhibit other effects that may be beneficial AD: huperzine has been demonstrated to reduce glutamate-induced cytotoxicity by antagonizing cerebral NMDA receptors. Importantly, this trial was designed to assess short-term symptomatic effects more likely attributable to AChEI or memantine-like effects than to neuroprotective mechanisms.

A total of 210 patients were enrolled in this study. The protocol was reviewed and approved by the institutional review board at each participating site. All research participants and caregivers gave written informed consent. Surrogate consent was used if criteria were met for its use. The Alzheimer's Disease Cooperative Study's Data and Safety Monitoring Board, which is advisory to the National Institute of Aging, provided safety oversight on an ongoing basis. The clinical trial identifier number for this study was NCT00083590. Blinded phase enrollment began June 2004 and last week 24 visit December 2007.

The present study represents an initial attempt to characterize the impact of short-term huperzine A treatment on individuals with mild to moderate AD. The primary endpoint for this trial, cognitive benefit as indicated by the change in ADAS-Cog score for the 200 μg BID dose at 16 weeks compared to placebo, did not indicate efficacy; we therefore cannot conclude that huperzine A provides cognitive enhancement in mild to moderate AD. However, the 200 μg BID did favorably influence MMSE scores at 16 weeks, and the 400 μg BID dose showed evidence of cognitive enhancement as measured by the ADAS-Cog and the MMSE. Thus, the results suggest a possible short-term symptomatic benefit of huperzine A, which requires confirmation in additional studies. Huperzine was generally well-tolerated at both doses tested.

Read more about about this trial at the link below

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269774/

Read more →

News

RSS
Tags
Andrew Kozlovski Andrew Kozlovski Reverb Press Feature Brainz Power Brainz Power feature- Princeton University Brainz Power Reverb Press Feature Huffington Post Reverb Press
href="https://twitter.com/http://twitter.com/brainzpower" data-widget-id="749836213486399488"> Tweets by @http://twitter.com/brainzpower